Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Recombinant anti-PD-1 humanized monoclonal antibody injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Sarcoma, Soft Tissue
1 trial -
Recombinant human endostatin
The First People's Hospital of Lianyungang
Stage III Non-small-Cell Lung Cancer
1 trial -
Regorafenib
United Therapeutics Europe Ltd
Adenocarcinoma of the Gastroesophageal Junction
1 trial -
Relacorilant
CORCEPT THERAPEUTICS INC
Recurrent Ovarian Cancer
1 trial -
Relacorilant 150 mg once daily (QD)
CORCEPT THERAPEUTICS INC
Ovarian Cancer
1 trial -
Relacorilant 150 mg once daily (QD)
CORCEPT THERAPEUTICS INC
Adenocarcinoma
1 trial -
Relacorilant with nab-paclitaxel
CORCEPT THERAPEUTICS INC
Solid Tumors
1 trial -
Relatlimab
Bristol-Myers Squibb
Neoplasms by Site
1 trial -
Relugolix
Takeda
Prostate Cancer
1 trial -
Repotrectinib (TPX-0005)
Turn Therapeutics
Advanced Solid Tumors
1 trial -
Revumenib
Syndax Pharmaceuticals
Leukemia
1 trial -
Revumenib
Syndax Pharmaceuticals
Colorectal Cancer
1 trial -
Revumenib
Syndax Pharmaceuticals
Acute Myeloid Leukemia
2 trials -
Rezvilutamide
Nanjing Zenshine Pharmaceuticals
Prostate Cancer
1 trial -
Rezvilutamide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Hormone-Sensitive Prostate Cancer
1 trial -
Rilvegostomig, Rilvegostomig
AstraZeneca AB
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).
1 trial -
Ritonavir
Abbott Australasia Pty Ltd
Sarcoma, Kaposi
1 trial -
Rituximab
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B Cell Lymphoma
1 trial -
Rituximab Paclitaxel Ruxolitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory Diffuse Large B-cell Lymphoma
1 trial -
Roginolisib
United Therapeutics Europe Ltd
Leukemia
1 trial -
Romidepsin
Takeda
Lymphoma, T-Cell, Peripheral
1 trial -
Romidepsin
Fondazione Telethon ETS
Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell lymphoma, NOS
1 trial -
Rozlytrek 200 mg hard capsules
Hoffmann-La Roche
Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
1 trial -
Rucaparib
United Therapeutics Europe Ltd
Cervical Cancer
1 trial -
S-1
United Therapeutics Europe Ltd
Advanced Non-Small Cell Lung Cancer
2 trials -
S-1
United Therapeutics Europe Ltd
Locally Advanced or Metastatic Pancreatic Cancer
1 trial -
S095018
Regeneron UK Limited
Non-small Cell Lung Cancer (NSCLC)
1 trial -
S095031-210
The George Institute
Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation
1 trial -
S095035
Tango Therapeutics
MTAP-deleted Solid Tumors
1 trial -
S1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Gastric Adenocarcinoma
1 trial -
S2023-056-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
S2023-413-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Acute Myeloid Leukemia
1 trial -
S227928
The George Institute
"Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"
1 trial -
SAKK 08/23
Ningbo Cancer Hospital
Metastatic castration-resistant prostate cancer
1 trial -
SAKK 16/18
Ningbo Cancer Hospital
Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)
1 trial -
SAKK 38/19
Ningbo Cancer Hospital
Disseminated large B-cell lymphoma
1 trial -
SAR444881
Regeneron UK Limited
Solid Tumors
1 trial -
SARS-CoV-2 mRNA Vaccine ARCT-021
Arcturus Therapeutics Holdings
Hematopoietic and Lymphatic System Neoplasm
1 trial -
SAVANNAH
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
1 trial -
SAVANNAH/D5084C0007
AstraZeneca AB
EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer
1 trial -
SCB01A
Biotech Pharmaceutical Co.,
Head and Neck Neoplasms
1 trial -
SCO101-001
Wuhan Createrna Science and Technology Co., Ltd
Metastatic Colorectal Cancer
1 trial -
SDREGN2810
Regeneron UK Limited
Advanced Non-Small Cell Lung Carcinoma
1 trial -
SDX-105
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
1 trial -
SELPERCATINIB, SELPERCATINIB
Wuhan Createrna Science and Technology Co., Ltd
Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.
1 trial -
SELUMETINIB for Metastatic breast cancer
Istituto Gentili S.r.l.
Metastatic breast cancer
1 trial -
SG+I
Xiyuan Hospital of China Academy of Chinese Medical Sciences
TNBC, Triple Negative Breast Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.